Current perspectives on cardiac amyloidosis

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 302, Issue 3, 2012, Pages

  Guan, Jian ^a   Mishra, Shikha ^a   Falk, Rodney H ^b   Liao, Ronglih ^a,b  

^a Cardiac Muscle Research Laboratory   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cardiomyocytes; Heart

Indexed keywords

AMYLOID; AMYLOID A PROTEIN; AMYLOID PRECURSOR PROTEIN; ANGIOTENSIN RECEPTOR ANTAGONIST; APOLIPOPROTEIN A1; ATRIAL NATRIURETIC FACTOR; BETA 2 MICROGLOBULIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BORTEZOMIB; CALCIUM CHANNEL BLOCKING AGENT; CYCLOPHOSPHAMIDE; CYSTATIN C; DEXAMETHASONE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GELSOLIN; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; INSULIN; LACTADHERIN; LACTOFERRIN; LENALIDOMIDE; MELPHALAN; PREALBUMIN; PRION PROTEIN; PROCALCITONIN; PROLACTIN; SERUM AMYLOID P; SMALL INTERFERING RNA; THALIDOMIDE;

ALPHA HELIX; ALZHEIMER DISEASE; BETA SHEET; COMPETITIVE INHIBITION; CONGESTIVE CARDIOMYOPATHY; DIAGNOSTIC ERROR; DRUG EFFICACY; DRUG MEGADOSE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; ENDOPLASMIC RETICULUM STRESS; EXTRACELLULAR MATRIX; HEART AMYLOIDOSIS; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE BIOPSY; HUMAN; HYPERTENSION; IMMUNE RESPONSE; IMMUNOTHERAPY; MOLECULAR DYNAMICS; MULTIPLE MYELOMA; NEUROTOXICITY; NOMENCLATURE; NONHUMAN; OSMOTIC MINIPUMP; OVERALL SURVIVAL; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PLASMA CELL DYSCRASIA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN CONFORMATION; PROTEIN FOLDING; RESTRICTIVE CARDIOMYOPATHY; REVIEW; RNA INTERFERENCE; SEX DIFFERENCE;

AMYLOIDOSIS; HEART DISEASES; HUMANS; MYOCARDIUM; MYOCYTES, CARDIAC;

EID: 84856448913     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00815.2011     Document Type: Review

References (112)

1. Ando Y, Nakamura M, Kai H, Katsuragi S, Terazaki H, Nozawa T, Okuda T, Misumi S, Matsunaga N, Hata K, Tajiri T, Shoji S, Yamashita T, Haraoka K, Obayashi K, Matsumoto K, Ando M, Uchino M. A novel localized amyloidosis associated with lactoferrin in the cornea. Lab Invest 82: 757-766, 2002.
2. Baden EM, Owen BA, Peterson FC, Volkman BF, Ramirez-Alvarado M, Thompson JR. Altered dimer interface decreases stability in an amyloidogenic protein. J Biol Chem 283: 15853-15860, 2008.
3. Baden EM, Randles EG, Aboagye AK, Thompson JR, Ramirez-Alvarado M. Structural insights into the role of mutations in amyloido-genesis. J Biol Chem 283: 30950-30956, 2008.
4. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer's disease. Lancet 377: 1019-1031, 2011.
5. Benson MD, James S, Scott K, Liepnieks JJ, Kluve-Beckerman B. Leukocyte chemotactic factor 2: a novel renal amyloid protein. Kidney Int 74: 218-222, 2008.
6. Benson MD, Kluve-Beckerman B, Zeldenrust SR, Siesky AM, Bodenmiller DM, Showalter AD, Sloop KW. Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle Nerve 33: 609-618, 2006.
7. Bergstrom J, Murphy C, Eulitz M, Weiss DT, Westermark GT, Solomon A, Westermark P. Codeposition of apolipoprotein A-IV and transthyretin in senile systemic (ATTR) amyloidosis. Biochem Biophys Res Commun 285: 903-908, 2001.
8. Bergstrom J, Murphy CL, Weiss DT, Solomon A, Sletten K, Hellman U, Westermark P. Two different types of amyloid deposits-apolipo-protein A-IV and transthyretin-in a patient systemic amyloidosis with. Lab Invest 84: 981-988, 2004.
9. Biolo A, Ramamurthy S, Connors LH, O'Hara CJ, Meier-Ewert HK, Soo Hoo PT, Sawyer DB, Seldin DC, Sam F. Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid deposition. Circ Heart Fail 1: 249-257, 2008.
10. Bodin K, Ellmerich S, Kahan MC, Tennent GA, Loesch A, Gilbert-son JA, Hutchinson WL, Mangione PP, Gallimore JR, Millar DJ, Minogue S, Dhillon AP, Taylor GW, Bradwell AR, Petrie A, Gill-more JD, Bellotti V, Botto M, Hawkins PN, Pepys MB. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 468: 93-97, 2010.
11. Brenner DA, Jain M, Pimentel DR, Wang B, Connors LH, Skinner M, Apstein CS, Liao R. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res 94: 1008-1010, 2004.
12. Chastan N, Baert-Desurmont S, Saugier-Veber P, Derumeaux G, Cabot A, Frebourg T, Hannequin D. Cardiac conduction alterations in a French family with amyloidosis of the Finnish type with the p. Asp187Tyr mutation in the GSN gene. Muscle Nerve 33: 113-119, 2006.
13. Cibeira MT, Sanchorawala V, Seldin DC, Quillen K, Berk JL, Dember LM, Segal A, Ruberg F, Meier-Ewert H, Andrea NT, Sloan JM, Finn KT, Doros G, Blade J, Skinner M. Outcome of AL amy-loidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood 118: 4346-4352, 2011.
14. Citron M. Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov 9: 387-398 2010.
15. Connors LH, Jiang Y, Budnik M, Theberge R, Prokaeva T, Bodi KL, Seldin DC, Costello CE, Skinner M. Heterogeneity in primary structure, post-translational modifications, and germline gene usage of nine full-length amyloidogenic kappa1 immunoglobulin light chains. Biochemistry 46: 14259-14271, 2007.
16. Davern S, Murphy CL, O'Neill H, Wall JS, Weiss DT, Solomon A. Effect of lysine modification on the stability and cellular binding of human amyloidogenic light chains. Biochim Biophys Acta 1812: 32-40, 2010.
17. Dey BR, Chung SS, Spitzer TR, Zheng H, Macgillivray TE, Seldin DC, McAfee S, Ballen K, Attar E, Wang T, Shin J, Newton-Cheh C, Moore S, Sanchorawala V, Skinner M, Madsen JC, Semigran MJ. Cardiac transplantation followed by dose-intensive melphalan and autol-ogous stem-cell transplantation for light chain amyloidosis and heart failure. Transplantation 90: 905-911, 2010.
18. Dillon CP, Sandy P, Nencioni A, Kissler S, Rubinson DA, Van Parijs L. Rnai as an experimental and therapeutic tool to study and regulate physiological and disease processes. Annu Rev Physiol 67: 147-173, 2005.
19. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, Greipp PR, Witzig TE, Lust JA, Rajkumar SV, Fonseca R, Zeldenrust SR, McGregor CG, Jaffe AS. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 22: 3751-3757, 2004.
20. Dispenzieri A, Kyle RA, Gertz MA, Therneau TM, Miller WL, Chandrasekaran K, McConnell JP, Burritt MF, Jaffe AS. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet 361: 1787-1789, 2003.
21. Dubrey S, Mendes L, Skinner M, Falk RH. Resolution of heart failure in patients with AL amyloidosis. Ann Intern Med 125: 481-484, 1996.
22. Dubrey SW, Cha K, Anderson J, Chamarthi B, Reisinger J, Skinner M, Falk RH. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM 91: 141-157, 1998.
23. Dubrey SW, Cha K, Skinner M, LaValley M, Falk RH. Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes. Heart 78: 74-82, 1997.
24. Eulitz M, Weiss DT, Solomon A. Immunoglobulin heavy-chain-associated amyloidosis. Proc Natl Acad Sci USA 87: 6542-6546, 1990.
25. Falk RH. Cardiac amyloidosis: a treatable disease, often overlooked. Circulation 124: 1079-1085, 2011.
26. Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation 112: 2047-2060, 2005.
27. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med 337: 898-909, 1997.
28. Falk RH, Dubrey SW. Amyloid heart disease. Prog Cardiovasc Dis 52: 347-361, 2010.
29. Gertz MA. Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 86: 180-186, 2011.
30. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, Merlini G, Moreau P, Ronco P, Sanchorawala V, Sezer O, Solomon A, Grateau G. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 79: 319-328, 2005.
31. Ghetti B, Tagliavini F, Takao M, Bugiani O, Piccardo P. Hereditary prion protein amyloidoses. Clin Lab Med 23: 65-85, viii, 2003.
32. Ghiso JA, Holton J, Miravalle L, Calero M, Lashley T, Vidal R, Houlden H, Wood N, Neubert TA, Rostagno A, Plant G, Revesz T, Frangione B. Systemic amyloid deposits in familial British dementia. J Biol Chem 276: 43909-43914, 2001.
33. Gianni D, Li A, Tesco G, McKay KM, Moore J, Raygor K, Rota M, Gwathmey JK, Dec GW, Aretz T, Leri A, Semigran MJ, Anversa P, Macgillivray TE, Tanzi RE, del Monte F. Protein aggregates and novel presenilin gene variants in idiopathic dilated cardiomyopathy. Circulation 121: 1216-1226, 2010.
34. Gibbs SD, Sattianayagam PT, Hawkins PN, Gillmore JD. Cardiac transplantation should be considered in selected patients with either AL or hereditary forms of amyloidosis: the UK National Amyloidosis Centre experience. Intern Med J 39: 786-787; author reply 787-788, 2009.
35. Gillmore JD, Hawkins PN. Drug insight: emerging therapies for amy-loidosis. Nat Clin Pract Nephrol 2: 263-270, 2006.
36. Gillmore JD, Tennent GA, Hutchinson WL, Gallimore JR, Lach-mann HJ, Goodman HJ, Offer M, Millar DJ, Petrie A, Hawkins PN, Pepys MB. Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis. Br J Haematol 148: 760-767, 2010.
37. Gong W, Liu ZH, Zeng CH, Peng A, Chen HP, Zhou H, Li LS. Amylin deposition in the kidney of patients with diabetic nephropathy. Kidney Int 72: 213-218, 2007.
38. Greene MJ, Sam F, Soo Hoo PT, Patel RS, Seldin DC, Connors LH. Evidence for a functional role of the molecular chaperone clusterin in amyloidotic cardiomyopathy. Am J Pathol 178: 61-68, 2011.
39. Haggqvist B, Naslund J, Sletten K, Westermark GT, Mucchiano G, Tjernberg LO, Nordstedt C, Engstrom U, Westermark P. Medin: an integral fragment of aortic smooth muscle cell-produced lactadherin forms the most common human amyloid. Proc Natl Acad Sci USA 96: 8669-8674, 1999.
40. Hamidi Asl K, Liepnieks JJ, Nakamura M, Parker F, Benson MD. A novel apolipoprotein A-1 variant, Arg173Pro, associated with cardiac and cutaneous amyloidosis. Biochem Biophys Res Commun 257: 584- 588, 1999.
41. Hamidi Asl L, Liepnieks JJ, Hamidi Asl K, Uemichi T, Moulin G, Desjoyaux E, Loire R, Delpech M, Grateau G, Benson MD. Hereditary amyloid cardiomyopathy caused by a variant apolipoprotein A1. Am J Pathol 154: 221-227, 1999.
42. Heegaard NH. Beta(2)-microglobulin: from physiology to amyloidosis. Amyloid 16: 151-173, 2009.
43. Hoppener JW, Lips CJ. Role of islet amyloid in type 2 diabetes mellitus. Int J Biochem Cell Biol 38: 726-736, 2006.
44. Hovey BM, Ward JE, Soo Hoo P, O'Hara CJ, Connors LH, Seldin DC. Preclinical development of siRNA therapeutics for AL amyloidosis. Gene Ther 18: 1150-1156, 2011.
45. Hrncic R, Wall J, Wolfenbarger DA, Murphy CL, Schell M, Weiss DT, Solomon A. Antibody-mediated resolution of light chain-associated amyloid deposits. Am J Pathol 157: 1239-1246, 2000.
46. Jacobson DR, Pastore RD, Yaghoubian R, Kane I, Gallo G, Buck FS, Buxbaum JN. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med 336: 466-473, 1997.
47. Kastritis E, Anagnostopoulos A, Roussou M, Toumanidis S, Pam-boukas C, Migkou M, Tassidou A, Xilouri I, Delibasi S, Psimenou E, Mellou S, Terpos E, Nanas J, Dimopoulos MA. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexa-methasone. Haematologica 92: 1351-1358, 2007.
48. Kaye GC, Butler MG, d'Ardenne AJ, Edmondson SJ, Camm AJ, Slavin G. Isolated atrial amyloid contains atrial natriuretic peptide: a report of six cases. Br Heart J 56: 317-320, 1986.
49. Kholova I, Niessen HW. Amyloid in the cardiovascular system: a review. J Clin Pathol 58: 125-133, 2005.
50. Kirkitadze MD, Condron MM, Teplow DB. Identification and characterization of key kinetic intermediates in amyloid beta-protein fibrillo-genesis. J Mol Biol 312: 1103-1119, 2001.
51. Klein AL, Hatle LK, Burstow DJ, Seward JB, Kyle RA, Bailey KR, Luscher TF, Gertz MA, Tajik AJ. Doppler characterization of left ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol 13: 1017-1026, 1989.
52. Klimtchuk ES, Gursky O, Patel RS, Laporte KL, Connors LH, Skinner M, Seldin DC. The critical role of the constant region in thermal stability and aggregation of amyloidogenic immunoglobulin light chain. Biochemistry 49: 9848-9857, 2010.
53. Kumar SK, Gertz MA, Lacy MQ, Dingli D, Hayman SR, Buadi FK, Short-Detweiler K, Zeldenrust SR, Leung N, Greipp PR, Lust JA, Russell SJ, Kyle RA, Rajkumar SV, Dispenzieri A. Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin Proc 86: 12-18, 2011.
54. Kyle RA. Amyloidosis: a convoluted story. Br J Haematol 114: 529-538, 2001.
55. Lemere CA, Masliah E. Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol 6: 108-119. 2010.
56. Levy E, Haltia M, Fernandez-Madrid I, Koivunen O, Ghiso J, Prelli F, Frangione B. Mutation in gelsolin gene in Finnish hereditary amy- loidosis. J Exp Med 172: 1865-1867, 1990.
57. Liao R, Jain M, Teller P, Connors LH, Ngoy S, Skinner M, Falk RH, Apstein CS. Infusion of light chains from patients with cardiac amyloid-osis causes diastolic dysfunction in isolated mouse hearts. Circulation 104: 1594-1597, 2001.
58. Linke RP, Joswig R, Murphy CL, Wang S, Zhou H, Gross U, Rocken C, Westermark P, Weiss DT, Solomon A. Senile seminal vesicle amyloid is derived from semenogelin I. J Lab Clin Med 145: 187-193, 2005.
59. Martin DJ, Ramirez-Alvarado M. Comparison of amyloid fibril formation by two closely related immunoglobulin light chain variable domains. Amyloid 17: 129-136, 2010.
60. Maury CP, Baumann M. Isolation and characterization of cardiac amyloid in familial amyloid polyneuropathy type IV (Finnish): relation of the amyloid protein to variant gelsolin. Biochim Biophys Acta 1096: 84-86, 1990.
61. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 349: 583-596, 2003.
62. Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol 29: 1924-1933, 2011.
63. Migrino RQ, Hari P, Gutterman DD, Bright M, Truran S, Schlundt B, Phillips SA. Systemic and microvascular oxidative stress induced by light chain amyloidosis. Int J Cardiol 145: 67-68, 2010.
64. Migrino RQ, Truran S, Gutterman DD, Franco DA, Bright M, Schlundt B, Timmons M, Motta A, Phillips SA, Hari P. Human microvascular dysfunction and apoptotic injury induced by AL amyloid-osis light chain proteins. Am J Physiol Heart Circ Physiol 301: H2305-H2312, 2011.
65. Munier FL, Korvatska E, Djemai A, Le Paslier D, Zografos L, Pescia G, Schorderet DF. Kerato-epithelin mutations in four 5q31-linked corneal dystrophies. Nat Genet 15: 247-251, 1997.
66. Murphy CL, Kestler DP, Foster JS, Wang S, Macy SD, Kennel SJ, Carlson ER, Hudson J, Weiss DT, Solomon A. Odontogenic amelo-blast-associated protein nature of the amyloid found in calcifying epithelial odontogenic tumors and unerupted tooth follicles. Amyloid 15: 89-95, 2008.
67. Murphy CL, Wang S, Williams T, Weiss DT, Solomon A. Characterization of systemic amyloid deposits by mass spectrometry. Methods Enzymol 412: 48-62, 2006.
68. Nowak M. Immunoglobulin kappa light chain and its amyloidogenic mutants: a molecular dynamics study. Proteins 55: 11-21, 2004.
69. Nuutinen T, Suuronen T, Kauppinen A, Salminen A. Clusterin: a forgotten player in Alzheimer's disease. Brain Res Rev 61: 89-104, 2009.
70. Obici L, Bellotti V, Mangione P, Stoppini M, Arbustini E, Verga L, Zorzoli I, Anesi E, Zanotti G, Campana C, Vigano M, Merlini G. The new apolipoprotein A-I variant leu(174)¡Ser causes hereditary cardiac amyloidosis, and the amyloid fibrils are constituted by the 93-residue N-terminal polypeptide. Am J Pathol 155: 695-702, 1999.
71. Palladini G, Campana C, Klersy C, Balduini A, Vadacca G, Perfetti V, Perlini S, Obici L, Ascari E, d'Eril GM, Moratti R, Merlini G. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 107: 2440-2445, 2003.
72. Palladini G, Lavatelli F, Russo P, Perlini S, Perfetti V, Bosoni T, Obici L, Bradwell AR, D'Eril GM, Fogari R, Moratti R, Merlini G. Circulating amyloidogenic free light chains and serum N-terminal natri-uretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 107: 3854-3858, 2006.
73. Palladini G, Merlini G. Transplantation vs. conventional-dose therapy for amyloidosis. Curr Opin Oncol 23: 214-220, 2011.
74. Palsdottir A, Snorradottir AO, Thorsteinsson L. Hereditary cystatin C amyloid angiopathy: genetic, clinical, and pathological aspects. Brain Pathol 16: 55-59, 2006.
75. Pepys MB, Hawkins PN, Booth DR, Vigushin DM, Tennent GA, Soutar AK, Totty N, Nguyen O, Blake CC, Terry CJ, Feest TG, Zalin AM, Hsuan JJ. Human lysozyme gene mutations cause hereditary systemic amyloidosis. Nature 362: 553-557, 1993.
76. Pepys MB, Herbert J, Hutchinson WL, Tennent GA, Lachmann HJ, Gallimore JR, Lovat LB, Bartfai T, Alanine A, Hertel C, Hoffmann T, Jakob-Roetne R, Norcross RD, Kemp JA, Yamamura K, Suzuki M, Taylor GW, Murray S, Thompson D, Purvis A, Kolstoe S, Wood SP, Hawkins PN. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 417: 254-259, 2002.
77. Peterson FC, Baden EM, Owen BA, Volkman BF, Ramirez-Alvarado M. A single mutation promotes amyloidogenicity through a highly promiscuous dimer interface. Structure 18: 563-570, 2010.
78. Phipps JE, Kestler DP, Foster JS, Kennel SJ, Donnell R, Weiss DT, Solomon A, Wall JS. Inhibition of pathologic immunoglobulin-free light chain production by small interfering RNA molecules. Exp Hematol 38: 1006-1013, 2010.
79. Poshusta TL, Sikkink LA, Leung N, Clark RJ, Dispenzieri A, Ramirez-Alvarado M. Mutations in specific structural regions of im-munoglobulin light chains are associated with free light chain levels in patients with AL amyloidosis. PLoS One 4: e5169, 2009.
80. Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, Salvi F, Ciliberti P, Pastorelli F, Biagini E, Coccolo F, Cooke RM, Bacchi-Reggiani L, Sangiorgi D, Ferlini A, Cavo M, Zamagni E, Fonte ML, Palladini G, Salinaro F, Musca F, Obici L, Branzi A, Perlini S. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 120: 1203-1212, 2009.
81. Reches M, Porat Y, Gazit E. Amyloid fibril formation by pentapeptide and tetrapeptide fragments of human calcitonin. J Biol Chem 277: 35475-35480, 2002.
82. Reece DE, Sanchorawala V, Hegenbart U, Merlini G, Palladini G, Fermand JP, Vescio RA, Liu X, Elsayed YA, Cakana A, Comenzo RL. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood 114: 1489-1497, 2009.
83. Ren R, Hong Z, Gong H, Laporte K, Skinner M, Seldin DC, Costello CE, Connors LH, Trinkaus-Randall V. Role of glycosaminoglycan sulfation in the formation of immunoglobulin light chain amyloid oli-gomers and fibrils. J Biol Chem 285: 37672-37682, 2010.
84. Rocken C, Shakespeare A. Pathology, diagnosis and pathogenesis of AA amyloidosis. Virchows Arch 440: 111-122, 2002.
85. Roig E, Almenar L, Gonzalez-Vilchez F, Rabago G, Delgado J, Gomez-Bueno M, Crespo-Leiro MG, Arizon JM, de la Fuente L, Manito N. Outcomes of heart transplantation for cardiac amyloidosis: subanalysis of the Spanish registry for heart transplantation. Am J Transplant 9: 1414-1419, 2009.
86. Sah DW, Aronin N. Oligonucleotide therapeutic approaches for Hun-tington disease. J Clin Invest 121: 500-507, 2011.
87. Sanchorawala V. Light-chain (AL) amyloidosis: diagnosis and treatment. Clin J Am Soc Nephrol 1: 1331-1341, 2006.
88. Sanchorawala V, Seldin DC, Magnani B, Skinner M, Wright DG. Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis. Bone Marrow Transplant 36: 597-600, 2005.
89. Sekijima Y, Kelly JW, Ikeda S. Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses. Curr Pharm Des 14: 3219-3230, 2008.
90. Seldin DC, Choufani EB, Dember LM, Wiesman JF, Berk JL, Falk RH, O'Hara C, Fennessey S, Finn KT, Wright DG, Skinner M, Sanchorawala V. Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis. Clin Lymphoma 3: 241-246, 2003.
91. Selkoe DJ. Folding proteins in fatal ways. Nature 426: 900-904, 2003.
92. Shah KB, Inoue Y, Mehra MR. Amyloidosis and the heart: a comprehensive review. Arch Intern Med 166: 1805-1813, 2006.
93. Shi J, Guan J, Jiang B, Brenner DA, Del Monte F, Ward JE, Connors LH, Sawyer DB, Semigran MJ, Macgillivray TE, Seldin DC, Falk R, Liao R. Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway. Proc Natl Acad Sci USA 107: 4188-4193, 2010.
94. Sikkink LA, Ramirez-Alvarado M. Cytotoxicity of amyloidogenic immunoglobulin light chains in cell culture. Cell Death Dis 1: e98, 2010.
95. Simms RW, Prout MN, Cohen AS. The epidemiology of AL and AA amyloidosis. Baillieres Clin Rheumatol 8: 627-634, 1994.
96. Sipe JD, Benson MD, Buxbaum JN, Ikeda S, Merlini G, Saraiva MJ, Westermark P. Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the International Society of Amyloidosis. Amyloid 17: 101-104, 2011.
97. Sipe JD, Cohen AS. Review: history of the amyloid fibril. J Struct Biol 130: 88-98, 2000.
98. Sitia R, Palladini G, Merlini G. Bortezomib in the treatment of AL amyloidosis: targeted therapy? Haematologica 92: 1302-1307, 2007.
99. Skinner M, Vaitukaitis JL, Cohen AS, Benson MD. Serum amyloid P-component levels in amyloidosis, connective tissue diseases, infection, and malignancy as compared to normal serum. J Lab Clin Med 94: 633-638, 1979.
100. Stangou AJ, Banner NR, Hendry BM, Rela M, Portmann B, Wendon J, Monaghan M, Maccarthy P, Buxton-Thomas M, Mathias CJ, Liepnieks JJ, O'Grady J, Heaton ND, Benson MD. Hereditary fibrin-ogen A alpha-chain amyloidosis: phenotypic characterization of a systemic disease and the role of liver transplantation. Blood 115: 2998-3007, 2010.
101. Stevens FJ. Four structural risk factors identify most fibril-forming kappa light chains. Amyloid 7: 200-211, 2000.
102. Suhr OB, Herlenius G, Friman S, Ericzon BG. Liver transplantation for hereditary transthyretin amyloidosis. Liver Transpl 6: 263-276, 2000.
103. Uversky VN. Intrinsic disorder in proteins associated with neurodegen-erative diseases. Front Biosci 14: 5188-5238, 2009.
104. Uversky VN, Oldfield CJ, Dunker AK. Intrinsically disordered proteins in human diseases: introducing the D2 concept. Annu Rev Biophys 37: 215-246, 2008.
105. Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR, Dogan A. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood 114: 4957-4959, 2009.
106. Wall J, Schell M, Murphy C, Hrncic R, Stevens FJ, Solomon A. Thermodynamic instability of human lambda 6 light chains: correlation with fibrillogenicity. Biochemistry 38: 14101-14108, 1999.
107. Wall JS, Gupta V, Wilkerson M, Schell M, Loris R, Adams P, Solomon A, Stevens F, Dealwis C. Structural basis of light chain amyloidogenicity: comparison of the thermodynamic properties, fibril-logenic potential and tertiary structural features of four Vlambda6 proteins. J Mol Recognit 17: 323-331, 2004.
108. Wally J, Kica G, Zhang Y, Ericsson T, Connors LH, Benson MD, Liepnieks JJ, Murray J, Skinner M, Comenzo RL. Identification of a novel substitution in the constant region of a gene coding for an amyloidogenic kappa1 light chain. Biochim Biophys Acta 1454: 49-56, 1999.
109. Wechalekar AD, Goodman HJ, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Safety and efficacy of risk-adapted cyclophosph-amide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood 109: 457-464, 2007.
110. Weiner HL, Frenkel D. Immunology and immunotherapy of Alzheimer's disease. Nat Rev Immunol 6: 404-416, 2006.
111. Westermark P, Eriksson L, Engstrom U, Enestrom S, Sletten K. Prolactin-derived amyloid in the aging pituitary gland. Am J Pathol 150: 67-73, 1997.
112. Yumlu S, Barany R, Eriksson M, Rocken C. Localized insulin-derived amyloidosis in patients with diabetes mellitus: a case report. Hum Pathol 40: 1655-1660, 2009.